1.
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
by Martins, Filipe
The lancet oncology, 2019, Vol.20 (1), p.e54-e64
2.
The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017
by Neal, Joseph M
Regional anesthesia and pain medicine, 2018, Vol.43 (2), p.113-123
3.
The prescribing cascade revisited
by Rochon, Paula A
The Lancet (British edition), 2017, Vol.389 (10081), p.1778-1780
4.
The American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2017 Version
by Neal, Joseph M
Regional anesthesia and pain medicine, 2018, Vol.43 (2), p.150-153
5.
Local Anesthetic Systemic Toxicity: A Review of Recent Case Reports and Registries
by Gitman, Marina
Regional anesthesia and pain medicine, 2018, Vol.43 (2), p.124-130
6.
The Mechanisms Underlying Lipid Resuscitation Therapy
by Fettiplace, Michael R
Regional anesthesia and pain medicine, 2018, Vol.43 (2), p.138-149
7.
Drug-induced acid-base disorders
by Kitterer, Daniel
Pediatric nephrology (Berlin, West), 2014, Vol.30 (9), p.1407-1423
8.
A Personalized Medicine Approach for Asian Americans with the Aldehyde Dehydrogenase 22 Variant
by Gross, Eric R
Annual review of pharmacology and toxicology, 2015, Vol.55 (1), p.107-127
9.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled tri...
by Park, Keunchil, Prof
The lancet oncology, 2016, Vol.17 (5), p.577-589
10.
Local Anesthetic Systemic Toxicity in Total Joint Arthroplasty: Incidence and Risk Factors in the United States From the National Inpatient Sample 1998–2013
by Rubin, Daniel S
Regional anesthesia and pain medicine, 2018, Vol.43 (2), p.131-137
11.
Severe cutaneous adverse reactions to drugs
by Duong, Tu Anh, Dr
The Lancet (British edition), 2017, Vol.390 (10106), p.1996-2011
12.
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
by Bachelot, Thomas, Dr
The lancet oncology, 2013, Vol.14 (1), p.64-71
13.
Adverse drug reactions: definitions, diagnosis, and management
by Edwards, I Ralph
The Lancet (British edition), 2000, Vol.356 (9237), p.1255-1259
14.
Development and evaluation of the medication-based index of physical function (MedIP)
by Hall, Courtney D
Age and ageing, 2017, Vol.46 (5), p.761-766
15.
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase...
by Xuan, Li
The lancet oncology, 2020, Vol.21 (9), p.1201-1212
16.
Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals
by Justice, Amy C
AIDS (London), 2018, Vol.32 (6), p.739-749
17.
Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA
by Grivas, Petros
Future oncology (London, England), 2019, Vol.15 (33), p.3809-3818
18.
The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology
by Ross, Colin J D
Thyroid (New York, N.Y.), 2010, Vol.20 (7), p.681-687
19.
Drug allergy
by Khan, David A., MD
Journal of allergy and clinical immunology, 2010, Vol.125 (2), p.S126-S137.e1
20.
Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study
by Naito, Yoichi
Breast cancer (Tokyo, Japan), 2019, Vol.27 (1), p.122-128
